Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COAction: Neoadjuvant Leuprorelin, Darolutamide or Both Prior to Radical Prostatectomy for Prostate Cancer
NCT06627530Phase 4Active, not recruiting
- Sponsor
- Brazilian Clinical Research Institute
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of darolutamide in prostate cancer (PCa) (3 arms), sponsored by Brazilian Clinical Research Institute. Primary endpoint: Minimal Residual Disease at 24 weeks. Started Feb 2025; status: active, not recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06627530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06627530.